Combination chemotherapy preceding surgery in osteogenic sarcoma
Van Oosterom, A.T.; Voûte, P.A.; Taminiau, A.H.; van der Eijken, J.W.
Progress in Clinical and Biological Research 201: 53-57
1985
ISSN/ISBN: 0361-7742 PMID: 3867903 Document Number: 249549
In 19 unselected subsequently entered non-metastatic patients with a normal osteogenic sarcoma two different just tolerable chemotherapy combinations were applied pre- and postoperatively. The median follow-up time after discontinuation of chemotherapy is 26+ months. Nine patients have failed, all showing pulmonary metastases, six have died despite several heavy salvage regimens. So the disease free survival rate is 53%. Longer follow-up in this group and the European Osteosarcoma Intergroup Study will be needed to clarify the value of neoadjuvant chemotherapy in this disease.